Evommune, Inc.
EVMN•NYSE•Healthcare•Biotechnology

About Evommune

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOLuis Pena
Founded2020
IPO DateNovember 6, 2025
Employees45
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSE (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.evommune.com
Phone(925) 247-4487
Address
1841 Page Mill Road, Suite 100 Palo Alto, California 94304 United States

Corporate Identifiers

CIK0002044725
CUSIP30054Y107
ISINUS30054Y1073
EIN85-0742575
SIC2834

Leadership Team & Key Executives

Luis C. Pena
Founder, President, Chief Executive Officer and Director
Kyle Carver CPA, M.B.A.
Chief Financial Officer
Gregory S. Moss Esq.
Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer
Dr. Eugene Andrew Bauer M.D.
Co-Founder, Chief Medical Officer and Director
Janice Drew M.P.H.
Executive Vice President of Operations
Dr. Jeegar Patel Ph.D.
Chief Scientific Officer
Dr. Lou Sehl Ph.D.
Senior Vice President of Technical Operations
Dr. Daniel J. Burge M.d.
Senior Vice President of Clinical Development